动物用药品市场依产品类型、给药途径、动物类型及分销管道划分－2025-2032年全球预测

预计到 2032 年，动物用药品市场规模将达到 393.7 亿美元，年复合成长率为 6.16%。

关键市场统计数据
基准年 2024	243.9亿美元
预计年份：2025年	259.1亿美元
预测年份 2032	393.7亿美元
复合年增长率 (%)	6.16%

针对不断变化的动物治疗环境，制定策略实施方案。重点阐述临床、商业和监管方面的变化，这些变化要求产业做出果断应对。

现代动物用药品领域正处于技术创新加速、监管审查日益严格以及终端用户期望不断变化这三者交汇的十字路口。近年来，该行业见证了护理模式的演变，更加重视预防医学、生物製药以及更精细的抗菌药物管理。这些动态正在再形成供应商和从业人员的行为，并促使他们在不同的治疗层级和给药方式之间重新平衡投资。

随着相关人员不断调整，清晰的策略基础至关重要。兽医和行业领导者正面临着许多压力，包括抗菌药物使用监管日益严格、对更安全、更有针对性的治疗方法的需求不断增长，以及在不同动物种类和护理环境下提供医疗服务的实际情况。此外，数位化管道和远端医疗的普及也开始影响产品的分销方式以及饲主获取治疗方案的方式。因此，市场参与企业必须重新评估其产品组合的优先事项、生产能力以及与临床终端使用者的互动模式，以保持竞争力。

从观察到策略的转变需要整合临床趋势和商业性现实。本导言概述了塑造该领域的关键力量，并为更深入的分析奠定了基础，包括变革性转变、关税的影响、细分市场主导的机会、区域动态、竞争定位，以及为希望将洞见转化为行动的领导者提供的实用建议。

具有重大影响的科学、监管和商业性变革正在改变动物治疗的优先事项，并重新定义如何为临床医生和饲主提供价值。

动物用药品领域的研发重点、製造地和商业模式正经历着变革性的转变。对生物製药和新一代疫苗的关注，以及对抗菌药物管理的重新重视，正促使研发人员致力于开发窄频谱药物、替代治疗方法和更先进的诊断工具以指南治疗。这些科学趋势与营运转型相呼应，建构更具韧性的供应链、灵活的生产模式以及采用合约开发和製造外包伙伴关係，正成为核心竞争力。

在商业性，通路动态正在不断演变。传统兽医诊所仍然是临床干预的中心，而线上药局和数位平台则扩大了服务覆盖范围。这种数位化，加上诊疗点数据收集的改进，为以结果为导向的产品和基于订阅的预防性项目创造了机会。动物饲养方式的改变，包括对伴侣动物健康投入的增加，正在改变不同治疗类别和给药途径的需求结构，进而影响处方决策和销售策略。

法律规范和支付方的期望都在不断变化，迫使企业制定能够证明产品安全性、有效性和实际价值的循证方案。这些变化共同要求企业采取整合策略，将科学创新与供应链敏捷性和商业性现代化结合，以获得永续优势。

2025年的关税压力将促使企业进行全面的供应链重组、区域製造业转移以及筹资策略调整，以保障市场进入和利润空间。

2025年生效的关税调整将为采购、定价和跨境物流带来更多复杂性，影响产品供应和筹资策略。製造商和经销商正在修订供应商合约和运输路线，以降低到岸成本上升并保护净利率，同时确保产品供应。这些调整通常需要优先考虑短期库存，并实现长期供应基础多元化，以降低集中采购带来的风险。

事实上，海关环境正在加速围绕区域製造和回流生产的讨论，尤其是在抗感染药感染疾病和疫苗等关键投入品和成品方面。企业也正在重新审视转让定价框架和分销协议，以控制跨区域成本。对于临床相关人员而言，重新强调成本效益高、循证的治疗方法选择，将促使他们关注处方合理化和在可行的情况下治疗方法替代。

展望未来，关税很可能仍将是商业规划中的一个结构性考虑因素，影响产能投资方向、优先考虑哪些合作伙伴关係以及如何建立分销网络以平衡竞争性定价和韧性等决策。

深度细分观点揭示了产品类型、给药途径、动物类型和分销管道的交汇点，从而创造了差异化的商业机会。

精细的市场区隔方法揭示了治疗需求和分销复杂性的交汇点。依产品类型分析，市场包括感染疾病、抗发炎药、抗寄生虫药和疫苗；感染疾病包括抗生素、抗真菌药物和抗病毒药；抗生素可进一步细分为头孢菌素类、氟喹诺酮类、Fluoroquinolones、青霉素类和四环霉素。这种细緻的划分揭示了不同的创新路径和管理考量，这些因素会影响研发重点和标籤策略。

给药途径也影响临床应用和商业性物流，吸入剂、注射剂、口服剂和局部剂型各有不同的配方、储存和给药限制；水产养殖（包括鱼虾）的疾病特征和给药挑战与伴侣动物（包括犬猫）不同；马科动物医学强调专门的治疗方法和火鸡给药方案；

分销管道进一步影响市场进入，线上药局、实体药局和兽医诊所各自拥有独特的客户接点和合规要求。整合这些细分市场有助于确定产品差异化、实证实践和商业模式客製化在哪些方面能够带来最大的策略回报。

对美洲、欧洲、中东和非洲以及亚太地区的策略性洞察突显了各地区在采纳、监管和分销需求方面的差异。

区域动态是製定有效商业和监管策略的核心。美洲市场的特点是拥有先进的兽医临床基础设施、宠物饲养率高，以及对高端生技药品和诊断产品的需求不断增长。由于各地区的政策和支付模式各不相同，因此在市场准入和报销谈判方面需要采取细緻入微的方法。

欧洲、中东和非洲呈现出多元化的市场格局，部分市场面临严格的监管环境，而有些市场则面临新的准入挑战。抗菌药物管理框架和统一的安全标准在欧洲部分地区已较为完善，而畜牧业集约化程度提高和兽医服务不断扩展的市场则可能蕴藏着重要的成长机会。同时，该地区的供应链和进口法规将影响本地生产或分销合作关係在哪些方面最为有利。

亚太地区的需求驱动因素多元化，涵盖了水产养殖业和大型畜牧业的蓬勃发展，以及城市中心伴侣动物照护的快速扩张。监管现代化、低温运输基础设施投资以及日益增长的数位化正在重塑产品的商业化模式。这些区域性洞察表明，量身定制的监管策略、差异化的产品定位和灵活的分销模式对于成功打入市场和永续成长至关重要。

竞争策略着重于整合疗法、数位化服务、稳健的供应链和实证实践，以在动物用药品市场中脱颖而出。

随着成熟的跨国动物用药品公司不断拓展产品组合，以及专注于生技药品、诊断和新型抗寄生虫药物的灵活专业企业涌现，竞争格局正在不断演变。领先企业优先考虑将治疗药物与数位化支援工具、疗效追踪和服务相结合的综合解决方案，以增强兽医和宠物饲主的参与度。策略合作和授权协议正被越来越多地用于加速新型治疗方法的普及，并分散生技药品和专科疗法的研发风险。

无论涉及何种物种，投资于灵活生产、健全品质体系和弹性供应链的公司，都能更好地应对关税波动和需求波动。同样重要的是，它们能够产生并传播高品质的临床证据，从而引起监管机构和临床医生的共鸣。随着竞争格局的日趋成熟，那些将产品创新与便捷的交付方式和引人注目的提案主张相结合的公司，将在临床偏好和采购决策方面获得优势。

领导者可以采取切实可行的策略行动，协调抗菌药物管理、在地化生产和以通路为中心的商业化，以确保永续优势。

产业领导者应优先采取一系列切实可行的措施，协调科学、供应和销售，以抓住近期机会并建立长期韧性。首先，推动抗菌药物管理倡议，同时进行标靶药物和诊断方法的研发，有助于满足不断变化的监管要求和临床医生对更安全、循证治疗的需求。其次，投资灵活的生产製造和区域生产能力，特别是针对关键生技药品和疫苗，可以降低关税和物流风险，并加快产品上市应对力。

在商业性，将治疗药物与数位化依从性工具和诊所层面的支持相结合，可以加强与兽医诊所的联繫，并使透过线上和线下药局销售的产品脱颖而出。细分市场策略应认识到，伴侣动物主人优先考虑便利性和先进的护理，而牲畜和家禽客户则重视价格实惠、易于管理且扩充性。最后，企业领导者应采用灵活的定价和分销模式，充分考虑当地的监管环境和通路经济效益，以在维持临床选择的同时，保持竞争力。

采用严谨的混合调查方法，结合一手和二手研究以及情境分析，以检验趋势和策略意义。

调查方法融合了量化和质化研究手段，旨在提供可靠且可操作的洞见。主要研究包括对价值链上的关键相关人员进行结构化访谈，访谈对象涵盖临床医生、采购专家和行业高管，以了解他们对临床需求、药品目录驱动因素和分销偏好的真实观点。次要研究则依赖监管文件、临床文献、专利申请和企业资料披露信息，以佐证研究趋势并识别新兴技术路径。

此分析架构运用細項分析方法，从产品类型、给药途径、动物类型和分销管道等方面入手，揭示需求模式和营运限制。情境分析用于压力测试供应链和关税敏感性，跨区域比较则揭示了监管和商业差异。数据品管和三角验证技术用于检验分析结果，研究结果经过具有动物治疗临床和商业经验的专家同行评审。

一项全面、前瞻性的研究，概述了科学、营运和商业性策略的整合将如何决定动物疗法的长期成功。

总之，由于科学创新、监管环境的演变以及商业性驱动因素的转变，动物用药品领域正经历重大变革。积极实践抗生素管理原则、投资于具有韧性和灵活性的生产製造，并商业性准入和扩大策略中。

最终，最成功的机构将是那些能够将洞察转化为协作执行的机构，它们将研发重点与切实可行的部署计划相结合，建立加速新型治疗方法普及的伙伴关係，并开发能够引起从业人员和所有者共鸣的商业模式。临床信誉、营运实力和商业性灵活性三者兼备，将决定在不断发展的动物治疗领域实现永续成功的道路。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 生物相似药的日益普及可降低治疗成本并扩大宠物用药范围
• 加强抗菌药物管理计划，以应对畜牧生产中的抗生素抗药性问题
• 增加对创新口服给药系统的投资，以提高宠物对药物的接受度和依从性
• 针对马和牛族群中新出现的病毒性疾病的物种特异性mRNA疫苗的进展
• 扩展的数位健康监测工具与药物治疗方案相结合，用于制定个人化的兽医护理计划

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 按产品类型的动物用药品市场

• 抗感染药物
  • 抗生素
    • 头孢菌素
    • Fluoroquinolones
    • 大环内酯类
    • 青霉素
    • 四环霉素
  • 抗真菌药物
  • 抗病毒药物
• 抗发炎药
• 杀寄生虫剂
• 疫苗

第九章 依给药途径分類的动物用药品市场

• 吸入
• 注射
• 口服
• 局部的

第十章 依动物类型分類的动物用药品市场

• 水产养殖
  • 鱼
  • 虾
• 伴侣动物
  • 狗
  • 猫科动物
• 马
• 家畜
  • 牛
  • 小反刍动物
  • 猪
• 家禽
  • 鸡
  • 火鸡

第十一章 按分销管道分類的动物用药品市场

• 网路药房
• 零售药房
• 兽医诊所

第十二章 按地区分類的动物用药品市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章动物用药品市场：依类别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国动物用药品市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Virbac SA
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals PLC
  • Vetoquinol SA
  • Norbrook Laboratories Limited

The Veterinary Drug Market is projected to grow by USD 39.37 billion at a CAGR of 6.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 24.39 billion
Estimated Year [2025]	USD 25.91 billion
Forecast Year [2032]	USD 39.37 billion
CAGR (%)	6.16%

A strategic introduction to the evolving veterinary therapeutics environment highlighting clinical, commercial, and regulatory forces that demand decisive industry responses

The contemporary veterinary drug landscape sits at the intersection of accelerating innovation, heightened regulatory scrutiny, and shifting end-user expectations. In recent years the industry has seen evolving modes of care that emphasize preventive health, biologics, and more nuanced antimicrobial stewardship. These dynamics are reshaping supplier and practitioner behavior, driving a rebalancing of investment across therapeutic classes and delivery formats.

As stakeholders adapt, the need for a clear strategic foundation becomes paramount. Veterinarians and industry leaders are navigating pressures from tighter regulations on antimicrobial use, rising demand for safer and more targeted therapies, and the operational realities of delivering care across diverse animal species and care settings. Moreover, the adoption of digital channels and telehealth has begun to influence how products are distributed and how owners access treatment options. Consequently, market participants must reassess portfolio priorities, manufacturing resilience, and engagement models with clinical end users to remain competitive.

Transitioning from observation to strategy requires synthesizing clinical trends with commercial realities. This introduction frames the essential forces shaping the field and sets the stage for deeper analysis on transformative shifts, tariff impacts, segmentation-driven opportunities, regional dynamics, competitive positioning, and practical recommendations for leaders seeking to translate insight into action.

High-impact scientific, regulatory, and commercial transformations are reshaping priorities in veterinary therapeutics and redefining how value is delivered to clinicians and owners

Transformative shifts are driving a reconfiguration of R&D priorities, manufacturing footprints, and commercial models within veterinary pharmaceuticals. The push toward biologics and next-generation vaccines has been accompanied by renewed attention to antimicrobial stewardship, prompting developers to pursue narrower-spectrum agents, alternative modalities, and enhanced diagnostic tools to guide therapy. These scientific trends are paralleled by operational transformations: supply chain resilience, flexible manufacturing, and the adoption of contract development and manufacturing partnerships are becoming core capabilities.

Commercially, channel dynamics are evolving as online pharmacies and digital platforms expand access while traditional veterinary hospitals remain central for clinical interventions. This digitization, combined with improved data capture at point of care, creates opportunities for outcomes-focused offerings and subscription-based preventative programs. Shifts in animal ownership patterns-such as higher investment in companion animal health-are altering demand mix across therapeutic categories and routes of administration, influencing formulary decisions and promotional strategies.

Regulatory frameworks and payer expectations are tightening, which compels companies to design evidence generation plans that demonstrate safety, efficacy, and real-world value. Collectively, these shifts require organizations to adopt integrated strategies that align scientific innovation with supply chain agility and commercial modernization to capture sustainable advantage.

Elevated tariff pressures in 2025 are prompting comprehensive supply chain redesigns, regional manufacturing shifts, and procurement strategies to safeguard access and margins

Tariff changes implemented in 2025 have introduced additional layers of complexity for sourcing, pricing, and cross-border logistics, affecting product availability and procurement strategies. Manufacturers and distributors are reassessing supplier contracts and transportation routes to mitigate increased landed costs and to preserve margins without compromising accessibility. These adjustments often necessitate near-term inventory prioritization and long-term supply base diversification to reduce exposure to concentrated sourcing risks.

In practice, the tariff environment has accelerated conversations around regional manufacturing and onshoring for critical inputs and finished products, particularly for essential classes such as anti-infectives and vaccines. Companies are also revisiting transfer pricing frameworks and distribution agreements to manage costs across geographies. For clinical stakeholders, the outcome is a heightened focus on formulary rationalization and therapeutic substitution where feasible, underpinned by a renewed emphasis on cost-effective, evidence-based therapy selection.

Looking ahead, tariffs are likely to remain a structural consideration in commercial planning, influencing decisions about where to invest in capacity, which partnerships to prioritize, and how to structure distribution networks to balance resilience with competitive pricing.

Deep segmentation perspectives reveal where product categories, administration routes, animal types, and distribution channels converge to create differentiated opportunities

A refined segmentation approach offers clarity on where therapeutic demand and distribution complexity converge. When analyzed by product category, the market encompasses anti-infectives, anti-inflammatories, parasiticides, and vaccines; within anti-infectives there are antibiotics, antifungals, and antivirals, and antibiotics can be further differentiated into cephalosporins, fluoroquinolones, macrolides, penicillins, and tetracyclines. This granularity reveals diverging innovation pathways and stewardship considerations that influence development priorities and labeling strategies.

Route of administration also shapes clinical adoption and commercial logistics, with inhalation, injectable, oral, and topical formats each presenting distinct formulation, storage, and administration constraints. Animal type segmentation shows differentiated demand drivers: aquaculture-comprising fish and shrimp-presents disease profiles and delivery challenges unlike those in companion animals, which include canines and felines; equine care emphasizes specialized therapeutics and dosing regimens; livestock, spanning cattle, small ruminants, and swine, requires scalable, cost-sensitive solutions; and poultry, represented by chickens and turkeys, demands approaches suited to mass administration and biosecurity.

Distribution channels further affect market access, where online pharmacies, retail pharmacies, and veterinary hospitals each offer unique customer touchpoints and compliance requirements. Synthesizing these segmentation lenses helps identify where product differentiation, targeted evidence, and tailored commercial models will deliver the greatest strategic return.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific reveal differentiated adoption, regulatory, and distribution imperatives

Regional dynamics are central to effective commercial and regulatory strategy. In the Americas, markets are characterized by advanced veterinary clinical infrastructure, high companion animal ownership, and growing demand for premium biologics and diagnostics; these features support robust innovation and early adoption of novel therapeutics. Policies and payer models vary across the region, requiring nuanced approaches to market entry and reimbursement discussions.

Europe, Middle East & Africa present a heterogeneous landscape where stringent regulatory expectations in some markets coexist with emerging access challenges in others. Antimicrobial stewardship frameworks and harmonized safety standards are prominent in parts of Europe, while key growth opportunities may be found in markets with rising livestock intensity and expanding veterinary services. Meanwhile, supply chain considerations and import regulations in this region influence where localized manufacturing or distribution partnerships are most beneficial.

Asia-Pacific exhibits diverse demand drivers, from intensifying aquaculture production and large-scale livestock operations to rapidly expanding companion animal care in urban centers. Regulatory modernization, investments in cold chain infrastructure, and increasing digital adoption are reshaping how products are commercialized. Together, these regional insights suggest that tailored regulatory strategies, differentiated product positioning, and adaptive distribution models are essential for successful market penetration and sustainable growth.

Competitive strategies are coalescing around integrated therapeutics, digital services, resilient supply chains, and evidence generation to outpace peers in veterinary markets

Competitive positioning is evolving as incumbent multinational animal health companies expand their portfolios alongside nimble specialized players focused on biologics, diagnostics, and novel antiparasitic agents. Leading firms are prioritizing integrated solutions that combine therapeutics with digital support tools, outcomes tracking, and services that enhance veterinarian and owner engagement. Strategic collaborations and licensing agreements are increasingly used to accelerate access to novel modalities and to spread the development risk associated with biologics and specialty therapeutics.

Operational excellence remains a differentiator: companies that have invested in flexible manufacturing, robust quality systems, and resilient supply chains are better positioned to navigate tariff volatility and fluctuating demand across animal types. Equally important is the ability to generate and communicate high-quality clinical evidence that resonates with both regulatory bodies and practitioners. As the competitive landscape matures, firms that align product innovation with accessible delivery formats and compelling value propositions will secure advantage in both clinical preference and procurement decisions.

Practical strategic actions for leadership to synchronize antimicrobial stewardship, regional manufacturing, and channel-focused commercialization for sustained advantage

Industry leaders should prioritize a set of actionable moves that align science, supply, and sales to capture near-term opportunities while building long-term resilience. First, advancing antimicrobial stewardship initiatives alongside development of targeted agents and diagnostics will meet evolving regulatory expectations and clinician demand for safer, evidence-based therapies. Second, investing in flexible manufacturing and regional capacity-especially for critical biologics and vaccines-will mitigate tariff and logistics exposure and accelerate market responsiveness.

Commercially, tailoring offerings by combining therapeutics with digital adherence tools and practice-level support will strengthen relationships with veterinary hospitals and differentiate products sold through online and retail pharmacies. Segment-focused strategies should recognize that companion animal owners prioritize convenience and advanced care, whereas livestock and poultry customers emphasize affordability, ease of administration, and scalability. Finally, leaders should adopt agile pricing and distribution models informed by regional regulatory landscapes and local channel economics to maintain competitiveness while preserving clinical choice.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary intelligence, and scenario analysis to validate trends and strategic implications

The research methodology blends quantitative and qualitative approaches to ensure robust, actionable findings. Primary research involved structured interviews with key stakeholders across the value chain, including clinical practitioners, procurement specialists, and industry executives, to capture real-world perspectives on clinical needs, formulary drivers, and distribution preferences. Secondary research incorporated regulatory documents, clinical literature, patent filings, and company disclosures to corroborate trends and identify emerging technology pathways.

Analytical frameworks applied include segmentation analysis across product categories, routes of administration, animal types, and distribution channels to reveal demand patterns and operational constraints. Scenario analysis was used to stress-test supply chain and tariff sensitivities, while cross-regional comparisons illuminated regulatory and commercial variances. Data quality controls and triangulation methods were employed throughout to validate insights, and findings were peer-reviewed by subject matter experts with clinical and commercial experience in veterinary therapeutics.

A forward-looking synthesis outlining how integrated scientific, operational, and commercial strategies will determine long-term success in veterinary therapeutics

In conclusion, the veterinary drug landscape is undergoing a period of substantive change driven by scientific innovation, regulatory evolution, and shifting commercial dynamics. Stakeholders who proactively integrate antimicrobial stewardship principles, invest in resilient and flexible manufacturing, and tailor commercial approaches to the unique needs of each animal segment and distribution channel will be best positioned to capture long-term value. Regional nuance remains a decisive factor: the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct regulatory, clinical, and logistical realities that must inform market entry and expansion strategies.

Ultimately, the most successful organizations will be those that translate insight into coordinated execution-aligning R&D priorities with practical deployment plans, building partnerships that accelerate access to novel modalities, and deploying commercial models that resonate with practitioners and owners. This synthesis of clinical credibility, operational strength, and commercial agility defines the pathway to sustainable success in the evolving veterinary therapeutics arena.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growing adoption of biosimilar therapeutics to reduce treatment costs and expand access for companion animals
• 5.2. Increased focus on antimicrobial stewardship programs to combat antibiotic resistance in livestock production
• 5.3. Rising investment in innovative oral delivery systems enhancing palatability and compliance in pet medications
• 5.4. Advancements in species-specific mRNA vaccines targeting emerging viral diseases in equine and bovine populations
• 5.5. Expansion of digital health monitoring tools integrated with drug regimens for personalized veterinary care plans

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Drug Market, by Product Category

• 8.1. Anti-Infectives
  • 8.1.1. Antibiotics
    • 8.1.1.1. Cephalosporins
    • 8.1.1.2. Fluoroquinolones
    • 8.1.1.3. Macrolides
    • 8.1.1.4. Penicillins
    • 8.1.1.5. Tetracyclines
  • 8.1.2. Antifungals
  • 8.1.3. Antivirals
• 8.2. Anti-Inflammatories
• 8.3. Parasiticides
• 8.4. Vaccines

9. Veterinary Drug Market, by Route Of Administration

• 9.1. Inhalation
• 9.2. Injectable
• 9.3. Oral
• 9.4. Topical

10. Veterinary Drug Market, by Animal Type

• 10.1. Aquaculture
  • 10.1.1. Fish
  • 10.1.2. Shrimp
• 10.2. Companion Animals
  • 10.2.1. Canines
  • 10.2.2. Felines
• 10.3. Equine
• 10.4. Livestock
  • 10.4.1. Cattle
  • 10.4.2. Small Ruminants
  • 10.4.3. Swine
• 10.5. Poultry
  • 10.5.1. Chickens
  • 10.5.2. Turkeys

11. Veterinary Drug Market, by Distribution Channel

• 11.1. Online Pharmacies
• 11.2. Retail Pharmacies
• 11.3. Veterinary Hospitals

12. Veterinary Drug Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Veterinary Drug Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Veterinary Drug Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Zoetis Inc.
  • 15.3.2. Elanco Animal Health Incorporated
  • 15.3.3. Merck & Co., Inc.
  • 15.3.4. Boehringer Ingelheim International GmbH
  • 15.3.5. Ceva Sante Animale S.A.
  • 15.3.6. Virbac S.A.
  • 15.3.7. Phibro Animal Health Corporation
  • 15.3.8. Dechra Pharmaceuticals PLC
  • 15.3.9. Vetoquinol S.A.
  • 15.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL VETERINARY DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. VETERINARY DRUG MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. VETERINARY DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. VETERINARY DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL VETERINARY DRUG MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 235. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 236. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 237. AMERICAS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
• TABLE 238. AMERICAS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
• TABLE 239. AMERICAS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 240. AMERICAS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 241. AMERICAS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
• TABLE 242. AMERICAS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
• TABLE 243. AMERICAS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
• TABLE 244. AMERICAS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 257. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 258. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 259. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
• TABLE 260. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
• TABLE 261. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 262. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 263. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
• TABLE 264. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
• TABLE 265. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
• TABLE 266. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
• TABLE 267. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 268. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 275. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 276. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 277. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 278. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 279. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 280. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 281. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
• TABLE 282. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
• TABLE 283. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 284. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 285. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
• TABLE 286. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
• TABLE 287. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
• TABLE 288. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
• TABLE 289. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 313. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 314. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 315. EUROPE VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 316. EUROPE VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 317. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 318. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 319. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 320. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
• TABLE 321. EUROPE VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 322. EUROPE VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 323. EUROPE VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 324. EUROPE VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 325. EUROPE VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
• TABLE 326. EUROPE VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
• TABLE 327. EUROPE VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 328. EUROPE VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 329. EUROPE VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
• TABLE 330. EUROPE VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
• TABLE 331. EUROPE VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
• TABLE 332. EUROPE VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
• TABLE 333. EUROPE VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 334. EUROPE VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 335. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 336. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 337. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
• TABLE 338. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
• TABLE 339. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 340. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 341. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD M